VIV RX: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.vivrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “VIV RX” on the pictured label, suggesting VIV RX is the compounder of those drugs when in fact it is not. Accordingly, the representations on your website that VIV RX is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

www.vivrx.com returned a live site on 2026-08-09 titled "Personalized, Science-Backed Weight Loss | Viv", with compound semaglutide and compound tirzepatide listed in the shop navigation alongside a get-started flow — an operating storefront rather than a closed one.

This is the smallest letter in the set, and that is exactly what makes it worth reading. There is no disputed efficacy claim here, no price comparison, no argument about whether a sentence oversells a result — the company's own marketing language is not quoted once. What FDA objected to is that the vial in the product photo carried the brand's name, which under FDA's reading tells you the brand made the drug. It did not; a compounding pharmacy did, and the letter says the pharmacy was never named. For a shopper, the practical question that raises is not whether the medicine works. It is who you would be dealing with if something went wrong — who mixed it, under whose licence, and whether the company whose name is on the box could answer that. A letter this narrow says nothing at all about the product's safety. It does say that the most basic fact on the label, the maker, was not the one printed there.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence VIV RX failed to respond.